Page Title
Clinical Trial Finder
Ask About Participating in This Study
Anti-InfectiveEnrolling
Study of CMTX-101 in adults with cystic fibrosis chronically infected with Pseudomonas aeruginosa , protocol number Clarametyx CMTX101-P1-CT002 SADThe following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Anti-InfectiveEnrolling
Study of CMTX-101 in adults with cystic fibrosis chronically infected with Pseudomonas aeruginosa , protocol number Clarametyx CMTX101-P1-CT002 SAD
This study will test the safety and tolerability of a single dose of CMTX-101 delivered through an IV infusion. CMTX-101 is a drug intended to help treat infections in the lung.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50% or greater
-
Number of Visits:
9
-
Length of Participation:
8 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More